about
Ampicillin resistance in Haemophilus influenzae from COPD patients in the UK.A limited CpG-containing oligodeoxynucleotide therapy regimen induces sustained suppression of allergic airway inflammation in mice.Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cellsMembrane nanoclusters of FcγRI segregate from inhibitory SIRPα upon activation of human macrophages.Functions of T cells in asthma: more than just T(H)2 cells.Acute Respiratory Distress Syndrome Neutrophils Have a Distinct Phenotype and Are Resistant to Phosphoinositide 3-Kinase Inhibition.Targeting phosphoinositide 3-kinase δ for the treatment of respiratory diseases.Superior activity of the type C class of ISS in vitro and in vivo across multiple species.PI3K inhibitors in inflammation, autoimmunity and cancer.Development of a Novel Quantitative Structure-Activity Relationship Model to Accurately Predict Pulmonary Absorption and Replace Routine Use of the Isolated Perfused Respiring Rat Lung Model.An investigation of the anti-inflammatory effects and a potential biomarker of PI3Kδ inhibition in COPD T cells.Altered fatty acid metabolism and reduced stearoyl-coenzyme a desaturase activity in asthma.IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment.Nonhuman primate models of asthmaFirst-in-Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well-Tolerated.A restricted subset of dendritic cells captures airborne antigens and remains able to activate specific T cells long after antigen exposure.The effect of phosphatidylinositol-3 kinase inhibition on matrix metalloproteinase-9 and reactive oxygen species release from chronic obstructive pulmonary disease neutrophils.Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation.Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD.Biomarkers measuring the activity of Toll-like receptor ligands in clinical development programs.Genome-wide transcription profiling in neutrophils in acute respiratory distress syndrome.The effects of repeated Toll-like receptors 2 and 4 stimulation in COPD alveolar macrophages.Histamine-secreting microbes are increased in the gut of adult asthma patients.Bronchoconstriction and airway hyperresponsiveness after ovalbumin inhalation in sensitized mice.Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.PI3Kδ hyper-activation promotes development of B cells that exacerbate Streptococcus pneumoniae infection in an antibody-independent mannerRepeated measurement of respiratory function and bronchoconstriction in unanesthetized miceLung inflammation and epithelial changes in a murine model of atopic asthmaDevelopment of airway hyperresponsiveness is dependent on interferon-gamma and independent of eosinophil infiltrationEosinophilic rhinitis accompanies the development of lower airway inflammation and hyper-reactivity in sensitized mice exposed to aerosolized allergenInvolvement of IL-16 in the induction of airway hyper-responsiveness and up-regulation of IgE in a murine model of allergic asthmaAirway epithelial Fas ligand expression: potential role in modulating bronchial inflammationAllergen-specific T cell responses to immunotherapy monitored by CD154 and intracellular cytokine expressionSafety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy SubjectsUse of autologous 99mTechnetium-labelled neutrophils to quantify lung neutrophil clearance in COPDA Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled AsthmaObesity and disease severity magnify disturbed microbiome-immune interactions in asthma patientsConverging TLR9 and PI3Kgamma signaling induces sterile inflammation and organ damageRelationship between Pharmacokinetics and Pharmacodynamic Responses in Healthy Smokers Informs a Once-Daily Dosing Regimen for NemiralisibInfluenza-induced monocyte-derived alveolar macrophages confer prolonged antibacterial protection
P50
Q33734409-632BAC33-22E1-46CB-AC07-A16674AC60DFQ36023560-8D0D204F-8B7D-45D8-BFCA-5454799176ECQ36247625-8F16A4DF-FF82-475D-9C02-64B063DD1B8BQ36306854-E9E5E01E-4523-4D16-A028-6EE10073DF39Q37253949-5A477906-7FCB-444E-BF48-479C76B6562AQ37345975-5D2B9F6D-A2CA-48BE-B784-052D0BAD8945Q38095575-013BD65B-4551-4648-9EA0-5EC6DB333209Q38330842-AB1D582D-35BD-463D-89C8-C3147F8EBF0AQ38532898-06BF6477-8EB5-49F1-A421-4F63C6B46936Q39612986-A84DF8F2-E377-4691-9B6D-4694D0CEEE3DQ40211028-19741FC5-9AD4-4DBE-9A2F-087B54CB994DQ40248822-97923F8B-CBDB-41B6-8167-57A42BDEAE7AQ40577440-AEE13B7E-D8A1-4B9E-B767-66BC5A559ACEQ42015594-560DC9BD-7645-455C-8BCB-4F8F2705A763Q46090169-52BBBAFA-F651-4A94-ABA1-4C742C831306Q46109501-84DB562D-EB22-4396-8935-38727965DE8FQ46568339-A976C9A2-AB03-418E-91A1-C38641F8D1F6Q46825011-47558F7B-22F4-4DBB-8824-54A56E558A4FQ47797457-97914D82-1983-4585-B5D5-8B11D26ED709Q47982842-2EB65F7E-C4C8-4380-AA41-EC13B0EA2A06Q48020377-92EA65B7-5621-4A10-BE47-7F25707FCC56Q51740589-E246BF98-71FC-4841-82EB-98CE9B2B7A78Q53965312-D2263083-9F3E-480B-85B7-5BAF9A4010A1Q54155075-D53A4DF6-E8A7-4934-BDF0-5DD09A910287Q54702413-F35E4ACF-B445-4B99-9562-9C802A33241EQ58793836-973CC017-2A28-455E-A294-0EB93346C165Q70984086-677C5122-ACB6-453B-B0A5-6FC91551AF1DQ71065076-A58B8A71-98D2-4DB2-8525-2B7CBF543900Q73155745-A43C2B38-2549-456A-9199-C3E10D031208Q74079954-AA103209-9B9F-4CCC-BDB8-729037A594E7Q74336636-85348A43-A870-48A1-88C5-FF5F231F4D58Q74408636-1DC81E86-57CC-40F6-8891-9C8BC6CDAC4EQ84094351-F242077C-1633-4CA3-9041-421E055D1C74Q90589351-EB7B86CC-3F3C-477A-88D2-218A0E682F10Q91185591-3DDEF730-4D03-40E6-90FD-C2B26CB58F17Q91457633-26A6346B-436A-4EF3-AAD0-42FFB0253EFEQ91972842-9480DF36-C067-4FF7-A30B-CCC67C578509Q91973253-F92752BC-5D43-487B-9111-9CE090D76E91Q92459864-FEA87E2D-23C8-461C-8819-E29F93731C42Q92611347-8B53A943-344D-4940-93FD-C1350A436A73
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-2339-4482
@en
name
Edith M Hessel
@ast
Edith M Hessel
@en
Edith M Hessel
@nl
type
label
Edith M Hessel
@ast
Edith M Hessel
@en
Edith M Hessel
@nl
prefLabel
Edith M Hessel
@ast
Edith M Hessel
@en
Edith M Hessel
@nl
P106
P108
P31
P496
0000-0002-2339-4482